Explore | Most Funded

7 investments found
Other

1928 Diagnostics

Join the fight against antibiotic resistance! We offer a Software-as-a-Service that revolutionises diagnostics of bacterial infections.
Funded SEK 22,191,741
Target SEK 10,000,000
Capital Target SEK 30,888,000
Min. Raise SEK 10,000,000
Percent of Equity Offered 30%
Valuation of equity SEK 90000000
End Date 04 May 2017
1 Startup Landala
View Investment
Other

EMPE Diagnostics

EMPE Diagnostics offers rapid and easy to use diagnostic solutions for infectious diseases with an initial focus on tuberculosis.
Funded SEK 9,722,385
Target SEK 4,000,000
Capital Target SEK 9,722,385
Min. Raise SEK 3,988,710
Percent of Equity Offered 42%
Valuation of equity SEK 23000000
End Date 10 August 2018
2 Growth
View Investment
Other

Cartana

CARTANA's research tool revolutionizes the analysis of tissue samples, giving biomedical researchers new information in their search for new treatments.
Funded SEK 9,432,780
Target SEK 5,517,366
Capital Target SEK 9,624,366
Min. Raise SEK 5,517,366
Percent of Equity Offered 38.5%
Valuation of equity SEK 24975000
End Date 22 September 2018
1 Startup
View Investment
Lipigon Pharmaceuticals AB
Other

Lipigon Pharmaceuticals AB

Lipigon utvecklar läkemedel för sjukdomar som beror på störningar i hur fetter hanteras i kroppen.
Funded SEK 7,996,815
Target SEK 7,996,815
Capital Target SEK 9,996,090
Min. Raise SEK 7,996,815
Percent of Equity Offered 33%
Valuation of equity SEK 30000000
End Date 11 February 2019
2 Growth
View Investment
Other

Attana

Our proven and patented technology enables faster and cheaper development of new safe drugs to people who need them to live a healthy life.
Funded SEK 6,419,181
Target SEK 4,000,000
Capital Target SEK 7,988,352
Min. Raise SEK 4,000,000
Percent of Equity Offered 29.63%
Valuation of equity SEK 27000000
End Date 12 October 2016
3 Expansion Stockholm
View Investment
Other

Inhalation Sciences

Inhalation Sciences produces game-changing R&D technology that maps and measures the health effects of inhaled air pollutants and pharmaceuticals.
Funded SEK 5,854,848
Target SEK 1,999,988
Capital Target SEK 5,964,000
Min. Raise SEK 1,999,988
Percent of Equity Offered 60%
Valuation of equity SEK 3962568
End Date 01 December 2016
3 Expansion Huddinge
View Investment